Literature DB >> 18417015

Myocardial fatty acid metabolism and cardiac performance in heart failure.

Helena Tuunanen1, Heikki Ukkonen, Juhani Knuuti.   

Abstract

It is well established that cardiac metabolism is abnormal in heart failure (HF). Experimental studies suggest that in severe HF, cardiac metabolism reverts to a more fetal-like substrate use characterized by enhanced glucose and downregulated free fatty acid (FFA) metabolism. Correspondingly, in humans, when FFA levels are similar, myocardial glucose metabolism is increased, and FFA metabolism is decreased. However, depression of left ventricular function and insulin resistance induces a shift back to greater FFA uptake and oxidation by increasing circulating FFA availability. Myocardial insulin resistance may further impair myocardial glucose uptake and lead to an energy depletion state. Experimental and preliminary clinical studies suggest that metabolic modulators enhancing myocardial glucose oxidation may improve cardiac function in patients with chronic HF. However, it has been found that acute FFA deprivation is harmful to the cardiac performance. Optimizing myocardial energy metabolism may serve as an additional approach for managing HF, but further studies are warranted.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18417015     DOI: 10.1007/s11886-008-0024-2

Source DB:  PubMed          Journal:  Curr Cardiol Rep        ISSN: 1523-3782            Impact factor:   2.931


  59 in total

1.  Modulation of myocardial energetics: emerging evidence for a therapeutic target in cardiovascular disease.

Authors:  David A Morrow; Michael M Givertz
Journal:  Circulation       Date:  2005-11-22       Impact factor: 29.690

2.  High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation.

Authors:  Que Liu; John C Docherty; John C T Rendell; Alexander S Clanachan; Gary D Lopaschuk
Journal:  J Am Coll Cardiol       Date:  2002-02-20       Impact factor: 24.094

3.  Therapeutic value of a cardioprotective agent in patients with severe ischaemic cardiomyopathy.

Authors:  L Brottier; J L Barat; C Combe; B Boussens; J Bonnet; H Bricaud
Journal:  Eur Heart J       Date:  1990-03       Impact factor: 29.983

4.  Reduced cardiac efficiency and altered substrate metabolism precedes the onset of hyperglycemia and contractile dysfunction in two mouse models of insulin resistance and obesity.

Authors:  Jonathan Buchanan; Pradip K Mazumder; Ping Hu; Gopa Chakrabarti; Matthew W Roberts; Ui Jeong Yun; Robert C Cooksey; Sheldon E Litwin; E Dale Abel
Journal:  Endocrinology       Date:  2005-09-01       Impact factor: 4.736

5.  The acute administration of trimetazidine modified myocardial perfusion and left ventricular function in 31 patients with ischaemic ventricular dysfunction.

Authors:  Mauro Feola; Alberto Biggi; Antonella Francini; Giovanni Leonardi; Flavio Ribichini; Valeria Ferrero; Eugenio Uslenghi
Journal:  Int J Cardiovasc Imaging       Date:  2004-08       Impact factor: 2.357

6.  Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.

Authors:  S Neubauer; M Horn; M Cramer; K Harre; J B Newell; W Peters; T Pabst; G Ertl; D Hahn; J S Ingwall; K Kochsiek
Journal:  Circulation       Date:  1997-10-07       Impact factor: 29.690

7.  Short- and long-term beneficial effects of trimetazidine in patients with diabetes and ischemic cardiomyopathy.

Authors:  G Fragasso; P M Piatti Md; L Monti; A Palloshi; E Setola; P Puccetti; G Calori; G D Lopaschuk; A Margonato
Journal:  Am Heart J       Date:  2003-11       Impact factor: 4.749

8.  Impact of aging on substrate metabolism by the human heart.

Authors:  Andrew M Kates; Pilar Herrero; Carmen Dence; Pablo Soto; Muthayyah Srinivasan; Deborah G Delano; Ali Ehsani; Robert J Gropler
Journal:  J Am Coll Cardiol       Date:  2003-01-15       Impact factor: 24.094

9.  Metabolic modulation with perhexiline in chronic heart failure: a randomized, controlled trial of short-term use of a novel treatment.

Authors:  Leong Lee; Ross Campbell; Michaela Scheuermann-Freestone; Rachel Taylor; Prasad Gunaruwan; Lynne Williams; Houman Ashrafian; John Horowitz; Alan G Fraser; Kieran Clarke; Michael Frenneaux
Journal:  Circulation       Date:  2005-11-22       Impact factor: 29.690

10.  Trimetazidine improves left ventricular function in diabetic patients with coronary artery disease: a double-blind placebo-controlled study.

Authors:  Giuseppe M C Rosano; Cristiana Vitale; Barbara Sposato; Giuseppe Mercuro; Massimo Fini
Journal:  Cardiovasc Diabetol       Date:  2003-11-28       Impact factor: 9.951

View more
  18 in total

Review 1.  Redox regulation of mitochondrial function.

Authors:  Diane E Handy; Joseph Loscalzo
Journal:  Antioxid Redox Signal       Date:  2012-02-03       Impact factor: 8.401

Review 2.  Lipid Use and Misuse by the Heart.

Authors:  P Christian Schulze; Konstantinos Drosatos; Ira J Goldberg
Journal:  Circ Res       Date:  2016-05-27       Impact factor: 17.367

3.  Metabolic remodeling of substrate utilization during heart failure progression.

Authors:  Liang Chen; Jiangping Song; Shengshou Hu
Journal:  Heart Fail Rev       Date:  2019-01       Impact factor: 4.214

Review 4.  Mitochondria in the human heart.

Authors:  H Lemieux; C L Hoppel
Journal:  J Bioenerg Biomembr       Date:  2009-04       Impact factor: 2.945

5.  Impact of diabetes on survival and right ventricular compensation in pulmonary arterial hypertension.

Authors:  Levi Benson; Evan L Brittain; Meredith E Pugh; Eric D Austin; Kelly Fox; Lisa Wheeler; Ivan M Robbins; Anna R Hemnes
Journal:  Pulm Circ       Date:  2014-06       Impact factor: 3.017

6.  Genome-wide association study of a heart failure related metabolomic profile among African Americans in the Atherosclerosis Risk in Communities (ARIC) study.

Authors:  Bing Yu; Yan Zheng; Danny Alexander; Teri A Manolio; Alvaro Alonso; Jennifer A Nettleton; Eric Boerwinkle
Journal:  Genet Epidemiol       Date:  2013-08-11       Impact factor: 2.135

7.  Associations between metabolomic compounds and incident heart failure among African Americans: the ARIC Study.

Authors:  Yan Zheng; Bing Yu; Danny Alexander; Teri A Manolio; David Aguilar; Josef Coresh; Gerardo Heiss; Eric Boerwinkle; Jennifer A Nettleton
Journal:  Am J Epidemiol       Date:  2013-06-20       Impact factor: 4.897

8.  Identification of New SRF Binding Sites in Genes Modulated by SRF Over-Expression in Mouse Hearts.

Authors:  Xiaomin Zhang; Gohar Azhar; Scott Helms; Brian Burton; Chris Huang; Ying Zhong; Xuesong Gu; Hong Fang; Weida Tong; Jeanne Y Wei
Journal:  Gene Regul Syst Bio       Date:  2011-07-12

9.  Chronic effects of palmitate overload on nutrient-induced insulin secretion and autocrine signalling in pancreatic MIN6 beta cells.

Authors:  Maria L Watson; Katherine Macrae; Anna E Marley; Harinder S Hundal
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

10.  Short-chain fatty acid propionate alleviates Akt2 knockout-induced myocardial contractile dysfunction.

Authors:  Linlin Li; Yinan Hua; Jun Ren
Journal:  Exp Diabetes Res       Date:  2011-09-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.